Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals, Inc. (DE:HDP1)
:HDP1
RESEARCH TOOLSreports
HDP1 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€15.42 - €30.30
Previous CloseN/A
Volume121.00
Average Volume (3M)188.00
Market Cap
€1.97B
Enterprise Value€2.67B
Total Cash (Recent Filing)$53.89M
Total Debt (Recent Filing)$115.86M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
May 08, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.76
Shares Outstanding126,098,114
10 Day Avg. Volume66
30 Day Avg. Volume188
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)353.70
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit751.83
Enterprise Value/Ebitda-4.60
Forecast
1Y Price Target
€38.96Price Target Upside94.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Drug Approval PotentialNDA filing places plozasiran on-track for potential approval for the treatment of familial chylomicronemia syndrome, which could generate near-term value for shareholders.
Strategic PartnershipsThe collaboration with SRPT has closed, and ARWR will receive $825mm, consisting of $500mm cash and $325mm as an equity investment priced at a 35% premium to 30-day volume weighted average price.
Bears Say
Risks And ChallengesRisks include clinical development risk, competitor risk, novel modality risk, commercialization risk, reimbursement risk, pricing risk, business development risk, capital market and dilution risk, and disruptions to clinical trials.
---
Options Prices
Currently, No data available
---
Ownership Overview
4.56% Insiders
19.16% Mutual Funds
2.28% Other Institutional Investors
45.52% Public Companies and Individual Investors
HDP1 FAQ
What was Arrowhead Pharmaceuticals, Inc.’s price range in the past 12 months?
Arrowhead Pharmaceuticals, Inc. lowest stock price was €15.42 and its highest was €30.30 in the past 12 months.
What is Arrowhead Pharmaceuticals, Inc.’s market cap?
Arrowhead Pharmaceuticals, Inc.’s market cap is €1.97B.
When is Arrowhead Pharmaceuticals, Inc.’s upcoming earnings report date?
Arrowhead Pharmaceuticals, Inc.’s upcoming earnings report date is May 08, 2025 which is in 59 days.
How were Arrowhead Pharmaceuticals, Inc.’s earnings last quarter?
Arrowhead Pharmaceuticals, Inc. released its earnings results on Feb 10, 2025. The company reported -€1.327 earnings per share for the quarter, missing the consensus estimate of -€0.387 by -€0.94.
Is Arrowhead Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals, Inc. pay dividends?
Arrowhead Pharmaceuticals, Inc. does not currently pay dividends.
What is Arrowhead Pharmaceuticals, Inc.’s EPS estimate?
Arrowhead Pharmaceuticals, Inc.’s EPS estimate is -0.1.
How many shares outstanding does Arrowhead Pharmaceuticals, Inc. have?
Arrowhead Pharmaceuticals, Inc. has 126,098,114 shares outstanding.
What happened to Arrowhead Pharmaceuticals, Inc.’s price movement after its last earnings report?
Arrowhead Pharmaceuticals, Inc. reported an EPS of -€1.327 in its last earnings report, missing expectations of -€0.387. Following the earnings report the stock price went down -2.514%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in DE:HDP1
---
Arrowhead Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€38.96 (94.42% Upside)
€38.96 (94.42% Upside)
Blogger Sentiment
Bullish
DE:HDP1 Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $196.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.88%
12-Months-Change
Fundamentals
Return on Equity
-600.68%
Trailing 12-Months
Asset Growth
61.86%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
---
HDP1 Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with major highlights such as the closing of a significant deal with Sarepta Therapeutics, upcoming launches, and strong pipeline advancements in obesity and CNS. However, increased operating expenses and a higher net loss were noted as lowlights, with some uncertainties regarding the timing of the CVOT for plozasiran.Read More>---
HDP1 Stock 12 Month Forecast
Average Price Target
€38.96
▲(94.42% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Arcturus Therapeutics
―
Moderna
―
Best Analysts Covering HDP1
1 Year
1 Year Success Rate
19/40 ratings generated profit
1 Year Average Return
+28.48%
reiterated a buy rating 28 days ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 47.50% of your transactions generating a profit, with an average return of +28.48% per trade.
---